Loading...
EVOK logo

Evoke Pharma, Inc.NasdaqCM:EVOK Stock Report

Market Cap US$23.7m
Share Price
US$11.00
US$18
38.9% undervalued intrinsic discount
1Y100.4%
7D0.5%
1D
Portfolio Value
​
View

Evoke Pharma, Inc.

NasdaqCM:EVOK Stock Report

Market Cap: US$23.7m

This company has been acquired

The company may no longer be operating, as it has been acquired. Find out why through their latest events.

Evoke Pharma (EVOK) Stock Overview

Operates as a specialty pharmaceutical company that focuses on the development and commercialization of drugs for the treatment of gastroenterological disorders and diseases. More details

EVOK fundamental analysis
Snowflake Score
Valuation3/6
Future Growth5/6
Past Performance0/6
Financial Health6/6
Dividends0/6

Rewards

Earnings are forecast to grow 121.1% per year

Earnings have grown 17.4% per year over the past 5 years

Trading at good value compared to peers and industry

Risk Analysis

Highly volatile share price over the past 3 months compared to the US market

Does not have a meaningful market cap ($24M)


EVOK Community Fair Values

Create Narrative

See what 8 others think this stock is worth. Follow their fair value or set your own to get alerts.

View all narratives

Evoke Pharma, Inc. Competitors

Price History & Performance

Summary of share price highs, lows and changes for Evoke Pharma
Historical stock prices
Current Share PriceUS$11.00
52 Week HighUS$11.00
52 Week LowUS$1.94
Beta-0.14
1 Month Change2.90%
3 Month Change110.73%
1 Year Change100.36%
3 Year Change-63.91%
5 Year Change-97.28%
Change since IPO-99.35%

Recent News & Updates

Recent updates

Analysis Article • Aug 19

Investors Still Aren't Entirely Convinced By Evoke Pharma, Inc.'s (NASDAQ:EVOK) Revenues Despite 31% Price Jump

NasdaqCM:EVOK 1 Year Share Price vs Fair Value Explore Evoke Pharma's Fair Values from the Community and select yours...
Analysis Article • Jul 30

Evoke Pharma (NASDAQ:EVOK) Is Using Debt Safely

David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...
Analysis Article • Jun 22

Evoke Pharma, Inc. (NASDAQ:EVOK) Might Not Be As Mispriced As It Looks After Plunging 27%

Evoke Pharma, Inc. ( NASDAQ:EVOK ) shares have had a horrible month, losing 27% after a relatively good period...
Analysis Article • Mar 16

Market Cool On Evoke Pharma, Inc.'s (NASDAQ:EVOK) Revenues Pushing Shares 29% Lower

Evoke Pharma, Inc. ( NASDAQ:EVOK ) shareholders won't be pleased to see that the share price has had a very rough...
Analysis Article • Jan 22

Evoke Pharma (NASDAQ:EVOK) Is Using Debt Safely

Warren Buffett famously said, 'Volatility is far from synonymous with risk.' So it might be obvious that you need to...
Seeking Alpha • Sep 20

Evoke to get US patent for nasal spray Gimoti

Evoke Pharma (NASDAQ:EVOK) said it will get a get patent from the U.S. Patent and Trademark Office (USPTO) for its nasal spray Gimoti. Gimoti is a nasal spray formulation of metoclopramide for relief of symptoms linked with acute and recurrent diabetic gastroparesis, a condition in which stomach takes too long to empty, the company said in a Sept. 20 press release. When granted, the patent will cover methods for treating moderate-to-severe gastroparesis with metoclopramide with an intranasal route of administration, Evoke noted. The company added that the patent will expire in 2037.
Seeking Alpha • Aug 10

Evoke Pharma Q2 GAAP loss per share narrows, revenue up

Evoke Pharma press release (NASDAQ:EVOK): Q2 GAAP EPS of -$0.71 (vs. -$0.85 Y/Y). Revenue of $0.46M (+91.7% Y/Y).
Seeking Alpha • Jul 06

Evoke Pharma gets Canadian patent linked to Gimoti nasal spray

Evoke Pharma (NASDAQ:EVOK) said the Canadian Intellectual Property Office granted a patent covering methods of use for nasal delivery of Gimoti's formulation, metoclopramide, to treat diabetic gastroparesis (DG). The patent titled “Nasal Formulations of Metoclopramide" expires in 2029, according to the company's July 6 press release. Evoke said the new patent corresponds to the two other U.S. patents under the same title that expire in 2029 and 2030, respectively. DG is a stomach problem related to diabetes which causes delayed gastric emptying.
Analysis Article • Oct 22

Does Evoke Pharma (NASDAQ:EVOK) Have A Healthy Balance Sheet?

Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...
Analysis Article • Jul 06

Does Evoke Pharma (NASDAQ:EVOK) Have A Healthy Balance Sheet?

Warren Buffett famously said, 'Volatility is far from synonymous with risk.' When we think about how risky a company...

Shareholder Returns

EVOKUS PharmaceuticalsUS Market
7D0.5%-2.3%0.3%
1Y100.4%35.9%26.2%

Return vs Industry: EVOK exceeded the US Pharmaceuticals industry which returned 23.3% over the past year.

Return vs Market: EVOK exceeded the US Market which returned 11.7% over the past year.

Price Volatility

Is EVOK's price volatile compared to industry and market?
EVOK volatility
EVOK Average Weekly Movement38.1%
Pharmaceuticals Industry Average Movement9.7%
Market Average Movement7.2%
10% most volatile stocks in US Market16.8%
10% least volatile stocks in US Market3.0%

Stable Share Price: EVOK's share price has been volatile over the past 3 months compared to the US market.

Volatility Over Time: EVOK's weekly volatility has increased from 32% to 38% over the past year.

About the Company

FoundedEmployeesCEOWebsite
20073Matt D'Onofriowww.evokepharma.com

Evoke Pharma, Inc. operates as a specialty pharmaceutical company that focuses on the development and commercialization of drugs for the treatment of gastroenterological disorders and diseases. It offers Gimoti, a metoclopramide nasal spray to treat symptoms associated with acute and recurrent diabetic gastroparesis in adults. The company markets its products to gastroenterologists, internal medicine specialists, primary care physicians, and select health care providers.

Evoke Pharma, Inc. Fundamentals Summary

How do Evoke Pharma's earnings and revenue compare to its market cap?
EVOK fundamental statistics
Market capUS$23.72m
Earnings (TTM)-US$5.23m
Revenue (TTM)US$14.42m
1.6x
P/S Ratio
-4.5x
P/E Ratio

Is EVOK overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
EVOK income statement (TTM)
RevenueUS$14.42m
Cost of RevenueUS$429.77k
Gross ProfitUS$13.99m
Other ExpensesUS$19.22m
Earnings-US$5.23m

Last Reported Earnings

Sep 30, 2025

Next Earnings Date

n/a

Earnings per share (EPS)-2.42
Gross Margin97.02%
Net Profit Margin-36.23%
Debt/Equity Ratio148.7%

How did EVOK perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/12/18 17:40
End of Day Share Price 2025/12/16 00:00
Earnings2025/09/30
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Evoke Pharma, Inc. is covered by 7 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Edward WooAscendiant Capital Markets LLC
David BuckB. Riley Securities, Inc.
Irina Rivkind KofflerCantor Fitzgerald & Co.